Show simple item record

AuthorBansal, Devendra
AuthorAbdulmajeed, Jazeel
AuthorAl-Shamali, Maha H.M.A.
AuthorAlbayat, Soha S.A.
AuthorHimatt, Sayed M.
AuthorCyprian, Farhan S.
AuthorChivese, Tawanda
AuthorMundodan, Jesha M.A.
AuthorKhogali, Hayat S.
AuthorBaaboura, Rekayahouda
AuthorKaleeckal, Anvar H.
AuthorKandy, Mujeeb C.
AuthorLatif, Ali Nizar
AuthorAl-Kuwari, Mohamed Ghaith
AuthorAl-Romaihi, Hamad Eid
AuthorAl Khal, Abdullatif
AuthorBertollini, Roberto
AuthorAl-Thani, Mohamed Hamad
AuthorFarag, Elmobashar
AuthorDoi, Suhail A.R.
Available date2023-02-21T07:48:07Z
Publication Date2022-07-01
Publication NameVaccines
Identifierhttp://dx.doi.org/10.3390/vaccines10071036
CitationBansal, D.; Abdulmajeed, J.; Al-Shamali, M.H.M.A.; Albayat, S.S.A.; Himatt, S.M.; Cyprian, F.S.; Chivese, T.; Mundodan, J.M.A.; Khogali, H.S.; Baaboura, R.; Kaleeckal, A.H.; Kandy, M.C.; Latif, A.N.; Al-Kuwari, M.G.; Al-Romaihi, H.E.; Al Khal, A.; Bertollini, R.; Al-Thani, M.H.; Farag, E.; Doi, S.A.R. Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease. Vaccines 2022, 10, 1036. https://doi.org/10.3390/vaccines10071036
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85133506258&origin=inward
URIhttp://hdl.handle.net/10576/40192
AbstractWaning immunity following administration of mRNA-based COVID-19 vaccines remains a concern for many health systems. We undertook a study to determine if recent reports of waning for severe disease could have been attributed to design-related bias by conducting a study only among those detected with a first SARS-CoV-2 infection. We used a matched case-control study design with the study base being all individuals with first infection with SARS-CoV-2 reported in the State of Qatar between 1 January 2021 and 20 February 2022. Cases were those detected with first SARS-CoV-2 infection requiring intensive care (hard outcome), while controls were those detected with first SARS-CoV-2 infection who recovered without the need for intensive care. Cases and controls were matched in a 1:30 ratio for the calendar month of infection and the comorbidity category. Duration and magnitude of conditional vaccine effectiveness against requiring intensive care and the number needed to vaccinate (NNV) to prevent one more case of COVID-19 requiring intensive care was estimated for the mRNA (BNT162b2/mRNA-1273) vaccines. Conditional vaccine effectiveness against requiring intensive care was 59% (95% confidence interval (CI), 50 to 76) between the first and second dose, and strengthened to 89% (95% CI, 85 to 92) between the second dose and 4 months post the second dose in persons who received a primary course of the vaccine. There was no waning of vaccine effectiveness in the period from 4 to 6, 6 to 9, and 9 to 12 months after the second dose. This study demonstrates that, contrary to mainstream reports using hierar-chical measures of effectiveness, conditional vaccine effectiveness against requiring intensive care remains robust till at least 12 months after the second dose of mRNA-based vaccines.
SponsorData collected as part of routine surveillance at the Ministry of Public Health was analyzed as part of this study. No separate funds were available for this study.
Languageen
PublisherMDPI
Subjectcase-control
conditional effectiveness
COVID-19
mRNA vaccine
vaccine effectiveness
waning
TitleDuration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease
TypeArticle
Issue Number7
Volume Number10
ESSN2076-393X
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record